NewCardio has announced that Dedicated Phase I has signed a Master Services Agreement (MSA) with NewCardio. Under terms of the agreement, Dedicated Phase I will receive a license to use NewCardio’s QTinno software solution in all TQT studies where fully automated readings are obtained.
It is anticipated that Dedicated Phase I, by utilizing QTinno in addition to its existing infrastructure, will be able to deliver the full range of TQT/QTc studies, becoming a turnkey provider of these studies to its customers.
Jason Bonanza, president and CEO of Dedicated Phase I, said: We are excited to add NewCardio’s QTinno solution to our advanced Core ECG laboratory. By integrating this important technological advancement with our existing solutions, we can deliver TQT/QTc studies for upload to the FDA digital ECG warehouse with greater accuracy and lower intrinsic variability than the legacy manual or semi-automated methodologies provide. In addition, we can reduce study timelines by several weeks, providing significant savings to customers on the overall cost of the study. The net result is that sponsors will receive higher quality study results and also save time and money. This is a win-win for Dedicated Phase I and our customers.
Vincent Renz, president and chief operating officer of NewCardio, said: This agreement will enable Dedicated Phase I to deliver quality TQT/QTc studies to its customers, to include both CROs and sponsors, with higher accuracy and lower variability in a more timely and cost-effective manner. Dedicated Phase I is truly an innovative organization, and this agreement demonstrates the firm’s commitment to the use of technology to improve quality and efficiency.
